WMWilliam J. Muller

William J. Muller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


William J. Muller has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Christopher G. Tortorice

    Institute for Molecular Biology and Biotechnology

    2 shared publications
  • Michael J. Rauh

    Queen's University

    2 shared publications
  • Robert D. Cardiff

    School of Medicine, University of California at Davis

    2 shared publications
  • Eran Robert Andrechek

    Department of Physiology, Michigan State University, East Lansing, USA

    1 shared publication
  • Frank L. Graham

    Cancer Research Group, Institute for Molecular Biology and Biotechnology,1 and Departments of Biology,2 Biochemistry,4 and Pathology,3 McMaster University, Hamilton, Ontario, Canada L8S 4K1, and Department of Pathology, School of Medicine, University of California at Davis, Davis California, 956165

    1 shared publication
  • John A. Hassell

    Cancer Research Group, Institute for Molecular Biology and Biotechnology,1 and Departments of Biology,2 Biochemistry,4 and Pathology,3 McMaster University, Hamilton, Ontario, Canada L8S 4K1, and Department of Pathology, School of Medicine, University of California at Davis, Davis California, 956165

    1 shared publication

Latest Publications

  • Accelerated Mammary Tumor Development in Mutant Polyomavirus Middle T Transgenic Mice Expressing Elevated Levels of Either the Shc or Grb2 Adapter Protein

    by Michael J. Rauh, Valerie Blackmore, Eran R. Andrechek, Christopher G. Tortorice, Roger Daly, Venus Ka-Man Lai, Tony Pawson, Robert D. Cardiff, Peter M. Siegel, William J. Muller

    The Grb2 and Shc adapter proteins play critical roles in coupling activated growth factor receptors to several cellular signaling pathways. To assess the role of these molecules in mammary epithelial development and tumorigenesis, we have generated transgenic mice which individually express the Grb2 and Shc proteins in the mammary epithelium. Although mammary epithelial cell-specific expression of Grb2 or Shc accelerated ductal morphogenesis, mammary tumors were rarely observed in these strains. To explore the potential role of these adapter proteins in mammary tumorigenesis, mice coexpressing either Shc or Grb2 and a mutant form of polyomavirus middle T (PyV mT) antigen in the mammary epithelium were generated. Coexpression of either Shc or Grb2 with the mutant PyV mT antigen resulted in a dramatic acceleration of mammary tumorigenesis compared to parental mutant PyV mT strain. The increased rate of tumor formation observed in these mice was correlated with activation of the epidermal growth factor receptor family and mitogen-activated protein kinase pathway. These observations suggest that elevated levels of the Grb2 or Shc adapter protein can accelerate mammary tumor progression by sensitizing the mammary epithelial cell to growth factor receptor signaling.


  • Requirement for Both Shc and Phosphatidylinositol 3′ Kinase Signaling Pathways in Polyomavirus Middle T-Mediated Mammary Tumorigenesis

    by Marc A. Webster, John N. Hutchinson, Michael J. Rauh, Senthil K. Muthuswamy, Martina Anton, Christopher G. Tortorice, Robert D. Cardiff, Frank L. Graham, John A. Hassell, William J. Muller

    Transgenic mice expressing the polyomavirus (PyV) middle T antigen (MT) develop multifocal mammary tumors which frequently metastasize to the lung. The potent transforming activity of PyV MT is correlated with its capacity to activate and associate with a number of signaling molecules, including the Src family tyrosine kinases, the 85-kDa Src homology 2 subunit of the phosphatidylinositol 3′ (PI-3′) kinase, and the Shc adapter protein. To uncover the role of these signaling proteins in MT-mediated mammary tumorigenesis, we have generated transgenic mice that express mutant PyV MT antigens decoupled from either the Shc or the PI-3′ kinase signaling pathway. In contrast to the rapid induction of metastatic mammary tumors observed in the strains expressing wild-type PyV MT, mammary epithelial cell-specific expression of either mutant PyV MT resulted in the induction of extensive mammary epithelial hyperplasias. The mammary epithelial hyperplasias expressing the mutant PyV MT defective in recruiting the PI-3′ kinase were highly apoptotic, suggesting that recruitment of PI-3′ kinase by MT affects cell survival. Whereas the initial phenotypes observed in both strains were global mammary epithelial hyperplasias, focal mammary tumors eventually arose in all female transgenic mice. Genetic and biochemical analyses of tumorigenesis in the transgenic strains expressing the PyV MT mutant lacking the Shc binding site revealed that a proportion of the metastatic tumors arising in these mice displayed evidence of reversion of the mutant Shc binding site. In contrast, no evidence of reversion of the PI-3′ kinase binding site was noted in tumors derived from the strains expressing the PI-3′ kinase binding site MT mutant. Tumor progression in both mutant strains was further correlated with upregulation of the epidermal growth factor receptor family members which are known to couple to the PI-3′ kinase and Shc signaling pathways. Taken together, these observations suggest that PyV MT-mediated tumorigenesis requires activation of both Shc and PI-3′ kinase, which appear to be required for stimulation of cell proliferation and survival signaling pathways, respectively.